Michael Wyllie

Taihua Plc is an investment holding company, which engages in the development, production, and distribution of active pharmaceutical ingredients. It operates through the following segments: Paclitaxel, Homoharringtonine, Traditional Chinese Medicine (TCM) product, and Forsythia. The Paclitaxel segment is extracted from the bark of the yew tree (Taxus), which is one of the main-stream treatments for cancer of the ovaries, breast, certain types of lung cancer, and cancer of the skin, and mucous membranes more commonly found in patients with acquired immunodeficiency syndrome. The Homoharringtonine segment is an alkaloid extracted from the branches and leaves of the Cephalotaxus tree and this drug has been prescribed for acute myeloid leukaemia and other cancers in China. The TCM product has recognition as a viable alternative health treatment and has been recognized by the World Health Organisation for its effectiveness in the treatment of certain forms of illnesses and diseases. The Forsythia segment known as lian qiao in Peoples's Republic of China is a flowering shrub, which is sold to alleviate flu and cold-like symptoms. The company was founded on August 29, 2006 and is headquartered in Xi'an, China.

Axellis, Inc. sells and distributes medical devices. Its products are used for oncology and cardiology. The company was founded in August 2007 and is headquartered in London, UK

Plethora Solutions Holdings Plc operates as a pharmaceutical company. It engages in the development and marketing of products for the treatment and management of urological disorders. The firm operates through the Plethora Development and The Urology Co. segments. The Plethora Development segment develops new pharmaceutical products. The Urology Co. segment sells and markets pharmaceutical and healthcare products. The company was founded by Michael Grant Wyllie and Neil Brent Stafford in December 2003 and is headquartered in Chalgrove, the United Kingdom.

Repros Therapeutics, Inc. is a development stage biopharmaceutical company, which focuses on the development of drugs to treat hormonal and reproductive systems disorders. Its products include Enclomiphene and Proellex. The company was founded on August 20, 1987 and is headquartered in The Woodlands, TX.

Part of Aytu Biopharma, Inc., GlycoMar Ltd. is a European center for marine biotechnology and glycobiology. The company is based in Oban, UK. The British company pursues untapped biological and chemical diversity to identify new drug candidates from marine organisms. GlycoMar was acquired by Rosewind Corp. on January 11, 2013 for $13.01 million.

Morvus Technology Ltd. discovers, develops and commercializes of novel drugs and technologies in the oncology field. Its products include clinical candidates, research portfolio and non-core programmes. The company was founded by Philip John Burke and Roger Geoffrey Melton in April 2004 and is headquartered in Carmarthen, the United Kingdom.